An interventional study of BALT GOLDBALL 2 detachable latex ballon and BALTACCIBDPE100 Microcatheter in Congenital Diaphragmatic Hernia, sponsored by Mauro H. Schenone. Recruiting at 1 site in United States. Open to female participants aged 18 Years to 50 Years. Per ClinicalTrials.gov, last updated 2026-03-19.
Sponsored by Mauro H. Schenone · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 45 studies in Hernias, Diaphragmatic, Congenital with a site in United States — 24 open to participants now, 28 under way, 2 of them phase 3. Hernias, Diaphragmatic, Congenital · United States.
Among the 45 studies in Hernias, Diaphragmatic, Congenital with a site in United States, this one is the 20th largest by planned enrollment of the 36 interventional ones that give a count, is one of 5 that started in 2026, is one of 28 with no phase, reaches primary completion later than 27 of the 27 other live ones, and was the 34th registered.
86 studies on the registry are indexed under Hernias, Diaphragmatic, Congenital; 39 are open to participants now.
Browse Hernias, Diaphragmatic, Congenital studies →24 of the 45 studies in Hernias, Diaphragmatic, Congenital with a site in United States are open now. Recruiting first, the newest first:
Dr Erin Perrone · Sites in United States
Ages 18+
Vincent Duron · Sites in United States
Ages 18+
The University of Texas Health Science Center, Houston · Sites in United States
Ages 0 mo–1 mo
Children's Hospital Medical Center, Cincinnati · Sites in United States
Ages 18–50 · Women only · Healthy volunteers
Johns Hopkins University · Sites in United States
Ages 18+ · Women only
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 32 Hernias, Diaphragmatic, Congenital studies recruiting now, 16 (50%) set no upper age limit and 16 (50%) stop at 75 or younger; 13 take children under 18; 6 take healthy volunteers.
This study: 18 Years to 50 Years · female · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
45 studies; the count open now beside each. This study's row is marked.
First in 2002; this study’s year is marked. 5 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 20 is below the median of 30 across 62 interventional studies indexed under Hernias, Diaphragmatic, Congenital.
Median enrollment 21 across the 36 interventional studies, 51 across the 8 observational. Of the 14 that completed or were terminated, 5 (36%) have results posted.
This tab as a report to print or save as PDF → With an account.
None of the 45 has an industry lead sponsor. The 10 most frequent:
Mauro H. Schenone is the lead sponsor of 2 studies on the registry; 2 are open to participants now.
Mauro H. Schenone has 1 study filed under Hernias, Diaphragmatic, Congenital — fewer than ten, so there is no comparison to draw.
2 of the studies in Hernias, Diaphragmatic, Congenital with a site in United States that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT04583644Hanmin LeePilot Trial of Fetoscopic Endoluminal Tracheal Occlusion (FETO) in Severe Left Congenital Diaphragmatic Hernia (CDH) | 2027-04 |
| NCT00950118Columbia UniversityDiaphragmatic Hernia Research & Exploration, Advancing Molecular Science | 2027-09 |
Add all 2 to your calendar (.ics) → With an account.
Among the 45 studies in Hernias, Diaphragmatic, Congenital with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The purpose of this research is to gather information on the safety and effectiveness of a procedure called Fetoscopic Endoluminal Tracheal Occlusion (FETO) at Mayo Clinic. The intent of the FETO procedure is to improve development of the lungs in fetuses diagnosed with severe congenital diaphragmatic hernia (CDH).
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants will undergo fetal endoscopic tracheal occlusion (FETO) surgical procedure between 27 weeks 0 days and 29 weeks 6 days gestation.
Device: BALT GOLDBALL 2 detachable latex ballon · Device: BALTACCIBDPE100 Microcatheter · Device: Storz fetoscopic operating sheath and miniature telescope/fetoscope
Inflated with fluid in the fetal trachea and provide with the occlusion necessary to promote lung growth.
Used to deliver the detachable balloon
Used to percutaneously enter though the maternal abdominal wall, uterus and into the amniotic cavity, fetal mouth, pharynx, larynx, into the trachea where the delivery catheter will be used to deliver the detachable balloon that will provide with the tracheal occlusion.
Technical success of the balloon placement procedure
The number of successful balloon placement procedures defined as balloon was correctly inflated and placed/secured in the trachea.
Time frame: Up to 29 weeks gestation
Technical success of balloon retrieval procedure
The number of successful balloon retrieval procedure defined as antenatal removal of the balloon.
Time frame: Up to 34 weeks gestation
Operative times
FETO placement and release operative times reported in minutes
Time frame: Up to 34 weeks gestation
Frequency of unplanned balloon removal
The frequency of non-emergent and emergent completion of FETO release (unplanned balloon removal)
Time frame: Up to 34 weeks gestation
Number of incidences of maternal complications
Maternal complications including preterm labor, premature rupture of membranes, oligohydramnios, polyhydramnios, chorioamnionitis
Time frame: Up to 41 weeks gestation
Gestational Age at Delivery
Gestation Age reported at time of delivery
Time frame: Up to 41 weeks gestation
Fetal Lung Growth as measured via Fetal Lung Volume
Fetal Lung Volume as measured via ultrasound
Time frame: Up to 24 months post partum
Fetal Lung Growth as measured via LHR
Lung area to head circumference Ratio (LHR) as measured via ultrasound
Time frame: Up to 24 months post partum
Fetal Survival
Survival at 30 days, discharge from the hospital and at 6 months if still hospitalized
Time frame: Up to 6 months post partum
Fetal Oxygen Dependency
Oxygen dependency graded as none, mild, moderate, severe as assessed by treating physician
Time frame: Up to 24 months post partum
Occurrence of severe pulmonary hypertension
Number of occurrence of severe pulmonary hypertension in infants based on echocardiogram
Time frame: Up to 24 months post partum
ECMO Support
Number of infants reported that required Extracorporeal membrane oxygenation (ECMO) support
Time frame: Up to 24 months post partum
Number of days in NICU
Number of days infant was in neonatal intensive care unit
Time frame: Up to 24 months post partum
Number of days of ventilator support
Number of reported days infants required ventilator support
Time frame: Up to 24 months post partum
Number of periventricular leukomalacia at < 2 months postnatally
Number of infants reported presence of periventricular leukomalacia at \< 2 months postnatally
Time frame: Up to 2 months post partum
Number of infant complications
Number of infants reporting the presence of: neonatal sepsis, intraventricular hemorrhage (grade 3 or higher), retinopathy of prematurity (grade 3 or higher) or gastro-esophageal reflux
Time frame: Up to 24 months post partum
Use of patch or muscle flap
Number of infants reported to require the use of patch or muscle flap
Time frame: Up to 24 months post partum
Maternal hospitalization
Number of reported days of maternal hospitalization
Time frame: Up to 24 months post partum
Route of delivery
Number of participants that delivered vaginally and via caesarean section
Time frame: Day 1 (post partum)
Plan to share: No
Start is estimated for Dec 2026; primary completion for Jul 2043, 199 months later.
Of 40 interventional studies with no phase under Hernias, Diaphragmatic, Congenital, half reached primary completion within 108 months of starting (the median), counting those still running; a quarter within 33 and three quarters within 133. This study's planned 199 months is above that.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
No contact was published for this record. The registry link below has the sponsor’s details.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Hernias, Diaphragmatic, Congenital →
Mauro H. Schenone